Skip to main content

komzifti

Generic: ziftomenib·Code: ziftomenib

komzifti: developed by 1 company · 1 FDA decision.

komzifti evidence translation

What we can confirm

What it means

Source-backed records connect komzifti to KURA; that link alone does not prove the drug works.

What to watch

Watch for new trials or company disclosures after the FDA record.
BioSniper AIPage evidence connected

Prepared research question

How could komzifti → KURA affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 0 study sponsors

Related indications

Relapsed or refractory acute myeloid leukemia (AML) with a susceptible NPM1 mutation

Study sponsors

No additional listed-company sponsor is linked.

Development Pipeline (1)
CompanyPhase
Kura Oncology, Inc. (KURA)
Relapsed or refractory acute myeloid leukemia (AML) with a s…
Approved
FDA Decisions1 records
Approval1 INDICATIONS AND USAGE KOMZIFTI is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 ( NPM1 ) mutation who have no satisfactory alternative treatment options [see Dosage and Administration ( 2.1 ), Clinical Pharmacology ( 12.1 ), and Clinical Studies ( 14 )] . KOMZIFTI is a menin inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptibl(KURA)FDA ↗
NDA220305Type 1 - New Molecular EntityOrphan DrugPriorityOralCapsule

Frequently asked questions

Who is developing komzifti?

komzifti is being developed by Kura Oncology, Inc..

What is komzifti's latest FDA decision?

The most recent tracked FDA decision for komzifti is Approval for 1 INDICATIONS AND USAGE KOMZIFTI is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 ( NPM1 ) mutation who have no satisfactory alternative treatment options [see Dosage and Administration ( 2.1 ), Clinical Pharmacology ( 12.1 ), and Clinical Studies ( 14 )] . KOMZIFTI is a menin inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptibl, dated November 13, 2025.